 Visit the TF Network Sites · Institutional Investor Center · Individual Investor Center |
| Download Plug-In |
| Real
Player 8 Basic Windows Media Player |
| Other Conference Calls |
| Other Feb 21 Calls Today's Calls |
| Call Details | |||
| Sucampo Pharmaceuticals, Inc. Conference Call to give an Overview of Commercial Launch Plans for RESCULA Scheduled to start Thu, Feb 21, 2013, 5:00 pm Eastern -- this event is ongoing now--
| |||
| About Sucampo Pharmaceuticals Inc (NasdaqGM:SCMP) | Other Calls | ||
| Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs based on prostones primarily in the Americas, Europe, and Asia. It offers prostone-based compounds for the treatment of gastrointestinal, vascular, respiratory, and central nervous system diseases and disorders. The company primarily markets Amitiza for the treatment of chronic idiopathic constipation in adults, as well as for irritable bowel syndrome with constipation in adult women. It also offers Rescula (unoprostone isopropyl) for the treatment of open-angle glaucoma and ocular hypertension. In addition, the company is developing Amitiza for the treatment of opioid-induced bowel dysfunction, which completed two Phase III clinical trials; Cobiprostone for the prevention of non-steroidal anti-inflammatory drug induced ulcers, which completed a Phase IIa clinical trial; SPI-017, a Phase I clinical trial product, for the treatment of Peripheral arterial disease; and SPI-3608 for the treatment of spinal stenosis, which is under preclinical trial. Additionally, it is conducting a preclinical trial of Rescula for dry age related macular degeneration; and preclinical trials of Cobiprostone for the treatment of chronic obstructive pulmonary disease and wound healing. Sucampo Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland. | |||
More Info: | |||
